Cyclacel Releases Promising Preclinical Data on Potential B-Cell Lymphoma Drug, Is Enrolling Patients for Phase 1 Study
News
Cyclacel Pharmaceuticals disclosed promising preclinical results of its drug candidate, CYC065, for the treatment of B-cell lymphoma in a poster presentation at the recent American Association for Cancer Research (AACR) annual meeting ... Read more